CareDx Highlights Strategic Transformation and Future Growth Opportunities at Goldman Sachs Healthcare Conference

CareDx, Inc. (NASDAQ: CDNA), a leading precision diagnostics company focused on transplant patient care, presented its latest business strategy, growth initiatives, and long-term vision during the Goldman Sachs 47th Annual Global Healthcare Conference. During the presentation, company executives discussed the organization's evolution into a precision medicine leader, expansion into oncology diagnostics, ongoing innovation in transplant monitoring, and plans to enhance profitability while driving sustainable growth.

Company Focuses on Precision Medicine and Advanced Diagnostics

Over the past several years, CareDx has transformed its business model to concentrate on areas where it believes it possesses significant competitive advantages. Management emphasized that the company's strategy revolves around molecular diagnostics, repeat-testing opportunities, strong reimbursement frameworks, and generating clinical evidence to support physician adoption.

The company is widely recognized for its transplant-focused diagnostic solutions that help physicians monitor organ transplant recipients for signs of rejection and complications. Through products such as AlloSure and AlloMap, CareDx has established itself as a major player in transplant healthcare diagnostics.

Executives noted that the company has performed more than one million rejection-monitoring tests and currently supports hundreds of transplant centers across the United States. This extensive experience has helped create a strong foundation for future innovation and expansion.

Strategic Acquisition of Naveris Expands Oncology Presence

One of the most significant topics discussed during the conference was CareDx's acquisition of Naveris, a company specializing in minimal residual disease (MRD) testing for viral-mediated cancers.

According to management, the acquisition aligns perfectly with CareDx's broader precision diagnostics strategy. Naveris developed NavDx, a test designed to detect residual disease in patients with HPV-associated cancers, particularly head and neck cancers.

The company believes the acquisition offers several strategic advantages:

• Entry into the rapidly growing oncology diagnostics market.
• Expansion beyond transplant medicine.
• Access to established reimbursement pathways.
• Opportunities for recurring testing revenue.
• Additional clinical evidence and intellectual property assets.

Executives highlighted that NavDx already benefits from Medicare coverage and has been supported by dozens of peer-reviewed scientific publications. Management described the technology as a market-leading solution with strong clinical validation.

Growing Importance of Minimal Residual Disease Testing

MRD testing is becoming increasingly important in modern cancer care because it allows physicians to detect signs of disease recurrence before symptoms become apparent through conventional diagnostic methods.

CareDx leadership explained that the ability to identify cancer recurrence earlier could improve patient outcomes and create substantial long-term opportunities for precision diagnostics companies.

The company expects Naveris to contribute meaningful revenue growth over the next several years while benefiting from CareDx's existing commercial infrastructure, physician relationships, and laboratory expertise.

Divestiture of Lab Products Business Supports Strategic Realignment

Another key development discussed at the conference was the company's decision to sell its laboratory products division.

Management stated that the divestiture generated approximately $170 million in proceeds and allows CareDx to focus resources on higher-growth areas, including precision diagnostics and oncology testing.

The company explained that the laboratory products business operated in a more regulated environment and delivered lower growth compared to the diagnostics segment. By reallocating capital and management attention, executives believe CareDx can improve overall operating performance and shareholder value.

The proceeds from the transaction also helped fund strategic investments, including the Naveris acquisition.

AlloHeme Represents a Major Pipeline Opportunity

A major focus of the conference presentation involved CareDx's AlloHeme program, which targets relapse monitoring for patients undergoing hematopoietic stem cell transplantation.

AlloHeme is being developed to monitor patients with conditions such as:

• Acute Myeloid Leukemia (AML)
• Myelodysplastic Syndromes (MDS)
• Other blood-related cancers

Company executives described AlloHeme as one of the most promising growth opportunities within the organization.

Clinical Study Results Show Encouraging Performance

Data from the ACROBAT clinical study demonstrated strong sensitivity and specificity in detecting relapse. Researchers observed that the test could identify disease recurrence more than 30 days earlier than some traditional monitoring approaches.

Management indicated that early detection can provide physicians with valuable time to adjust treatment strategies and potentially improve patient outcomes.

Before commercialization, the company plans to complete additional analytical verification studies, secure regulatory approvals, and pursue reimbursement coverage.

CareDx currently anticipates a commercial launch during 2027, with broader reimbursement opportunities potentially becoming available thereafter.

Continued Strength in Transplant Diagnostics Business

While the company is expanding into oncology, transplant diagnostics remains the foundation of CareDx's business.

Executives reported continued growth across heart, kidney, and lung transplant monitoring programs despite relatively stable transplant procedure volumes nationwide.

Management explained that growth has been driven primarily by:

• Higher adoption rates among existing customers.
• Expanded clinical utilization.
• Increasing physician awareness.
• Growing body of supporting clinical evidence.
• Improved integration with healthcare systems.

Heart Transplant Monitoring Advances

CareDx highlighted growing adoption of HeartCare, a non-invasive monitoring solution for heart transplant recipients.

Clinical studies have demonstrated that HeartCare provides prognostic information regarding graft dysfunction and cardiovascular complications. Physicians increasingly view the technology as a tool that may reduce reliance on invasive biopsy procedures.

Kidney Transplant Testing Remains a Key Growth Driver

Kidney transplantation continues to represent one of the largest market opportunities for CareDx.

Management noted that testing demand remains strong across both surveillance monitoring and diagnostic evaluations performed when physicians suspect possible organ rejection.

The company believes there remains significant room for further market penetration within kidney transplant programs throughout the United States.

Expansion of Digital Healthcare Ecosystem

Beyond laboratory testing, CareDx continues investing in digital health solutions designed to improve physician workflows and patient management.

The company has developed multiple software platforms that assist transplant centers with:

• Patient monitoring.
• Clinical decision support.
• Data management.
• Workflow optimization.
• Care coordination.

According to management, approximately 70% of transplant centers currently utilize at least one CareDx digital product.

Epic Integration Creates Additional Opportunities

Executives discussed ongoing integration efforts with Epic Systems, one of the largest electronic health record providers in the healthcare industry.

By embedding CareDx ordering and reporting capabilities directly within Epic workflows, the company aims to simplify test adoption and improve physician access to diagnostic information.

Management reported positive early feedback from healthcare providers participating in implementation programs.

Addressing Reimbursement Challenges

Like many diagnostics companies, CareDx continues to navigate an evolving reimbursement environment.

Management discussed potential impacts from proposed Medicare reimbursement policy changes related to transplant testing.

While acknowledging possible financial headwinds, executives expressed confidence that demand for the company's diagnostic services will remain strong because physicians increasingly rely on molecular testing to guide clinical decision-making.

The company also emphasized that commercial insurers often establish their own coverage policies independent of Medicare decisions.

Financial Performance and Profitability Initiatives

CareDx leadership outlined several initiatives aimed at enhancing profitability while maintaining investment in growth opportunities.

These initiatives include:

• Laboratory operational efficiencies.
• Technology platform consolidation.
• Revenue cycle improvements.
• Enhanced reimbursement management.
• Strategic capital allocation.

Management reported confidence in the company's ability to achieve long-term margin expansion while supporting innovation across multiple business segments.

Capital Allocation Strategy

The company continues evaluating opportunities across three primary areas:

1. Organic business investment.
2. Strategic acquisitions.
3. Share repurchase programs.

Executives indicated they believe the company remains well-positioned financially, supported by a strong balance sheet and significant cash resources.

Long-Term Vision for Growth

Looking ahead, CareDx intends to build upon its leadership position in transplant diagnostics while establishing a stronger presence in oncology and precision medicine.

The company's strategy focuses on developing high-value diagnostic tests that address serious medical conditions where early detection and continuous monitoring can significantly improve patient outcomes.

Management believes future growth will be supported by several factors:

• Expanding transplant test utilization.
• Commercialization of AlloHeme.
• Integration and growth of Naveris.
• Continued digital health adoption.
• Increasing demand for precision medicine solutions.

Industry Trends Support CareDx's Strategy

The healthcare industry continues shifting toward personalized medicine, molecular diagnostics, and non-invasive testing technologies. These trends align closely with CareDx's core capabilities.

As healthcare providers increasingly seek tools that enable earlier disease detection and individualized treatment decisions, the demand for advanced diagnostic solutions is expected to grow substantially.

CareDx believes its expertise in molecular testing, extensive clinical evidence, and established customer relationships position the company favorably to capitalize on these long-term market trends.

Conclusion

During the Goldman Sachs Global Healthcare Conference, CareDx presented a comprehensive vision for its future, emphasizing precision diagnostics, oncology expansion, transplant innovation, and operational excellence. The company's acquisition of Naveris, continued development of AlloHeme, strong transplant testing growth, and expanding digital healthcare ecosystem highlight a broader transformation beyond its traditional transplant roots.

While reimbursement dynamics and competitive pressures remain considerations, management expressed confidence that CareDx's technology platform, clinical evidence base, and strategic focus on high-value diagnostics will support sustainable growth in the years ahead. As precision medicine continues to evolve, CareDx appears committed to remaining at the forefront of innovation in both transplant care and oncology diagnostics.

Source: Information summarized and rewritten from public conference discussion materials and company-related disclosures.

#CareDx #CDNA #PrecisionMedicine #HealthcareInnovation #SlimScan #GrowthStocks #CANSLIM